Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | euchromatic histone-lysine N-methyltransferase 2 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Trichomonas vaginalis | set domain proteins, putative | Get druggable targets OG5_131470 | All targets in OG5_131470 |
Onchocerca volvulus | Get druggable targets OG5_131470 | All targets in OG5_131470 | |
Brugia malayi | Pre-SET motif family protein | Get druggable targets OG5_131470 | All targets in OG5_131470 |
Loa Loa (eye worm) | pre-SET domain-containing protein family protein | Get druggable targets OG5_131470 | All targets in OG5_131470 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | cyclic-nucleotide gated cation channel | 0.0128 | 0.0519 | 0.1414 |
Echinococcus multilocularis | voltage gated potassium channel | 0.016 | 0.0879 | 0.0879 |
Echinococcus multilocularis | potassium voltage gated channel subfamily H | 0.016 | 0.0879 | 0.0879 |
Echinococcus multilocularis | cyclic nucleotide gated cation channel alpha 3 | 0.0128 | 0.0519 | 0.0519 |
Trichomonas vaginalis | voltage and ligand gated potassium channel, putative | 0.032 | 0.2718 | 1 |
Echinococcus granulosus | potassium:sodium hyperpolarization activated | 0.0128 | 0.0519 | 0.0519 |
Brugia malayi | Voltage-gated potassium channel, HERG (KCNH2)-related. C. elegans unc-103 ortholog | 0.0403 | 0.3668 | 1 |
Trichomonas vaginalis | set domain proteins, putative | 0.0286 | 0.2324 | 0.8209 |
Echinococcus multilocularis | potassium voltage gated channel subfamily H | 0.0403 | 0.3668 | 0.3668 |
Loa Loa (eye worm) | hypothetical protein | 0.016 | 0.0879 | 0.2397 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0435 | 0.4029 | 1 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0115 | 0.0361 | 0.0895 |
Echinococcus multilocularis | hyperpolarization activated cyclic | 0.0128 | 0.0519 | 0.0519 |
Onchocerca volvulus | 0.0286 | 0.2324 | 0.5 | |
Echinococcus multilocularis | potassium:sodium hyperpolarization activated | 0.0128 | 0.0519 | 0.0519 |
Schistosoma mansoni | voltage-gated potassium channel | 0.016 | 0.0879 | 0.2182 |
Loa Loa (eye worm) | hypothetical protein | 0.0358 | 0.315 | 0.8586 |
Echinococcus multilocularis | hyperpolarization activated cyclic | 0.0128 | 0.0519 | 0.0519 |
Schistosoma mansoni | 60S ribosomal protein L21 | 0.0115 | 0.0361 | 0.0895 |
Schistosoma mansoni | cyclic-nucleotide-gated cation channel | 0.0128 | 0.0519 | 0.1287 |
Schistosoma mansoni | cyclic-nucleotide-gated cation channel | 0.0128 | 0.0519 | 0.1287 |
Loa Loa (eye worm) | voltage and ligand gated potassium channel | 0.0403 | 0.3668 | 1 |
Trichomonas vaginalis | voltage and ligand gated potassium channel, putative | 0.032 | 0.2718 | 1 |
Brugia malayi | Voltage-gated potassium channel, EAG (KCNH1)-related. C. elegans egl-2 ortholog | 0.016 | 0.0879 | 0.2397 |
Schistosoma mansoni | hyperpolarization activated cyclic nucleotide-gated potassium channel | 0.0128 | 0.0519 | 0.1287 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0435 | 0.4029 | 1 |
Echinococcus granulosus | voltage gated potassium channel | 0.016 | 0.0879 | 0.0879 |
Echinococcus granulosus | cyclic nucleotide gated cation channel | 0.0128 | 0.0519 | 0.0519 |
Brugia malayi | Pre-SET motif family protein | 0.0251 | 0.1927 | 0.5253 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0128 | 0.0519 | 0.1287 |
Echinococcus granulosus | cyclic nucleotide gated cation channel alpha 3 | 0.0128 | 0.0519 | 0.0519 |
Echinococcus granulosus | hyperpolarization activated cyclic | 0.0128 | 0.0519 | 0.0519 |
Echinococcus multilocularis | cyclic nucleotide gated cation channel | 0.0128 | 0.0519 | 0.0519 |
Schistosoma mansoni | hyperpolarization activated cyclic nucleotide-gated potassium channel | 0.0128 | 0.0519 | 0.1287 |
Schistosoma mansoni | voltage-gated potassium channel | 0.016 | 0.0879 | 0.2182 |
Brugia malayi | Cyclic-nucleotide gated cation channel | 0.0128 | 0.0519 | 0.1414 |
Loa Loa (eye worm) | hypothetical protein | 0.0128 | 0.0519 | 0.1414 |
Schistosoma mansoni | cyclic-nucleotide-gated cation channel | 0.0128 | 0.0519 | 0.1287 |
Echinococcus granulosus | cyclic nucleotide gated cation channel | 0.0128 | 0.0519 | 0.0519 |
Echinococcus granulosus | potassium voltage gated channel subfamily H | 0.016 | 0.0879 | 0.0879 |
Echinococcus granulosus | potassium voltage gated channel subfamily H | 0.0403 | 0.3668 | 0.3668 |
Loa Loa (eye worm) | pre-SET domain-containing protein family protein | 0.0251 | 0.1927 | 0.5253 |
Loa Loa (eye worm) | cyclic-nucleotide gated cation channel | 0.0128 | 0.0519 | 0.1414 |
Echinococcus granulosus | hyperpolarization activated cyclic | 0.0128 | 0.0519 | 0.0519 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 1.122 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b: Cytotox Counterscreen. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588855, AID588860] | ChEMBL. | No reference |
Potency (functional) | 7.9433 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404] | ChEMBL. | No reference |
Potency (functional) | = 28.1838 um | PUBCHEM_BIOASSAY: qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent). (Class of assay: confirmatory) [Related pubchem assays: 1002 (Confirmation Concentration-Response Assay for Inhibitors of AmpC Beta-Lactamase (assay with detergent)), 585 (Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent) - a screen old NIH MLSMR collection), 584 (Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent) - a screen of the old NIH MLSMR collection), 1003 (Confirmation Cuvette-Based Assay for Inhibitors of AmpC Beta-Lactamase (assay with detergent))] | ChEMBL. | No reference |
Potency (binding) | = 31.6228 um | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | ChEMBL. | No reference |
Potency (functional) | 31.6228 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent). (Class of assay: confirmatory) [Related pubchem assays: 2158 (Confirmation qHTS Assay for Inhibitors of Cruzain), 2249 (Probe Development Summary of Promiscuous Inhibitors (Artifacts) of Cruzain), 2161 (qHTS Assay for Inhibitors of Papain: Counterscreen for Cruzain Assay), 1478 (qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent))] | ChEMBL. | No reference |
Potency (functional) | 56.2341 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of JMJD2A-Tudor Domain. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504402] | ChEMBL. | No reference |
Potency (functional) | 70.7946 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of BAZ2B. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504391] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.